|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_ocn948296971 |
| 003 |
OCoLC |
| 005 |
20231120112106.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160429s2016 enk ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d OPELS
|d N$T
|d YDXCP
|d OCLCF
|d YDX
|d UPM
|d U3W
|d D6H
|d AU@
|d WYU
|d LQU
|d S2H
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 958084149
|a 958392409
|a 1066462332
|a 1105179746
|a 1105560687
|a 1162054571
|
| 020 |
|
|
|a 9780323428668
|q (electronic bk.)
|
| 020 |
|
|
|a 0323428665
|q (electronic bk.)
|
| 020 |
|
|
|a 9780323428897
|
| 020 |
|
|
|a 0323428894
|
| 020 |
|
|
|z 9780323428668
|q (print)
|
| 035 |
|
|
|a (OCoLC)948296971
|z (OCoLC)958084149
|z (OCoLC)958392409
|z (OCoLC)1066462332
|z (OCoLC)1105179746
|z (OCoLC)1105560687
|z (OCoLC)1162054571
|
| 050 |
|
4 |
|a TA418.9.N35
|
| 072 |
|
7 |
|a TEC
|x 009000
|2 bisacsh
|
| 072 |
|
7 |
|a TEC
|x 035000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 620.1/15
|2 23
|
| 245 |
0 |
0 |
|a Nanobiomaterials in drug delivery :
|b applications of nanobiomaterials /
|c edited by Alexandru Mihai Grumezescu.
|
| 264 |
|
1 |
|a Kidlington, Oxford, UK :
|b William Andrew is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed May 9, 2016).
|
| 505 |
0 |
|
|a Front Cover; Nanobiomaterials in Drug Delivery; Copyright Page; Contents; List of contributors; Preface of the series; Preface; About the Series (Volumes I-XI); About Volume IX; 1 Nanobiomaterials in drug delivery; Abbreviations; 1.1 Introduction; 1.1.1 Parameters of Delivery of Nanoparticles into Biological Systems; 1.1.2 Intratumor Drug Release; 1.1.3 Biological Clearance; 1.1.4 Toxicity of Nanoparticles; 1.2 Preparation and Characterization of Nanomaterials; 1.2.1 Preparation; 1.2.2 Characterization; 1.2.2.1 Physicochemical characterization.
|
| 505 |
8 |
|
|a 1.3 Nanotechnology-Assisted Formulating of Poorly Water-Soluble Compounds1.4 Biodegradable Polymers Used in Controlled Drug Delivery; 1.5 Multifunctional Nanomaterials for Cancer Therapy; 1.5.1 Targeting; 1.5.2 Imaging; 1.5.3 Chemotherapy; 1.6 Chemical Conjugation of Nanomaterials; 1.6.1 pH-Sensitive Linkages Used for Bioconjugation of Nanomaterials; 1.6.2 Other Chemical Linkages Used for Bioconjugation of Nanomaterials; 1.7 Conclusions; Acknowledgments; References; 2 Dendrimers in drug delivery; 2.1 Introduction; 2.2 Mechanisms of Interaction Between Dendrimers and Drug Molecules.
|
| 505 |
8 |
|
|a 2.3 Dendrimers as Carriers of Various Types of Drugs2.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); 2.3.2 Anticancer Drugs; 2.3.3 Other Drugs; 2.4 Routes of Administration of Drug-Dendrimers Complexes; 2.4.1 Dendrimers in Intravenous Drug Delivery; 2.4.2 Dendrimers in Oral Drug Delivery; 2.4.3 Dendrimers in Transdermal Drug Delivery; 2.4.4 Dendrimers in Ocular Drug Delivery; 2.4.5 Dendrimers in Pulmonary Drug Delivery; 2.5 Conclusions and Further Prognosis; Acknowledgments; References; 3 Lipid nanoparticles as non-viral vectors for siRNA delivery: concepts and applications.
|
| 505 |
8 |
|
|a 3.1 Introduction3.2 siRNA: Definition, Mechanism, and Applications; 3.3 Hurdles for siRNA Delivery; 3.4 Strategies to Overcome the Hurdles of siRNA Delivery; 3.4.1 Chemical Modifications in siRNA; 3.4.2 Physical Methods for siRNA Delivery; 3.4.3 Viral Carriers for siRNA Delivery; 3.4.4 Non-viral Carriers for siRNA Delivery; 3.5 Liposomes: The Influence of Charge and Lipid Composition for siRNA Delivery; 3.5.1 Cationic Lipid-Based siRNA Delivery Systems; 3.5.2 Neutral Lipid-Based siRNA Delivery Systems; 3.5.3 Anionic Lipid-Based siRNA Delivery Systems; 3.5.4 Stealth Liposomes.
|
| 505 |
8 |
|
|a 3.6 Targeted Delivery of siRNA-Loaded Liposomes3.7 Combined Therapy of siRNA-Loaded Liposomes and Conventional Small-Molecule Drugs; 3.8 siRNA-Loaded Liposomes Associated with Physical Methods; 3.9 siRNA-Loaded Liposomes: Clinical Studies; 3.10 Conclusions and Perspectives; References; 4 Nanobiomaterials: Novel nanoplatforms for protein and peptide delivery; 4.1 Introduction; 4.2 Proteins/Peptides as Therapeutics; 4.2.1 Group I-Protein Therapeutics with Enzymatic or Regulatory Activity; 4.2.2 Group II-Protein Therapeutics with Special Targeting Activity; 4.2.3 Group III-Proteinaceous Vaccines.
|
| 650 |
|
0 |
|a Nanostructured materials.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
0 |
|a Nanobiotechnology.
|
| 650 |
|
6 |
|a Nanomat�eriaux.
|0 (CaQQLa)201-0258061
|
| 650 |
|
6 |
|a Nanobiotechnologie.
|0 (CaQQLa)000286131
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
7 |
|a TECHNOLOGY & ENGINEERING
|x Engineering (General)
|2 bisacsh
|
| 650 |
|
7 |
|a TECHNOLOGY & ENGINEERING
|x Reference.
|2 bisacsh
|
| 650 |
|
7 |
|a Nanobiotechnology
|2 fast
|0 (OCoLC)fst01894713
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 650 |
|
7 |
|a Nanostructured materials
|2 fast
|0 (OCoLC)fst01032630
|
| 700 |
1 |
|
|a Grumezescu, Alexandru Mihai,
|e editor.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323428668
|z Texto completo
|
